How do core autism traits and associated symptoms relate to quality of life? Findings from the Longitudinal European Autism Project

Bethany FM Oakley1, Julian Tillmann1,2, Jumana Ahmad1,3, Daisy Crawley1, Antonia San José Cáceres1,4, Rosemary Holt5, Tony Charman1,6, Tobias Banaschewski7, Jan Buitelaar8,9, Emily Simonoff1,6, Declan Murphy1,6 and Eva Loth1 and The EU-AIMS LEAP Group

Abstract
Previous studies have reported reduced quality of life in autism. Improving quality of life for autistic people is, therefore, a key priority for clinical research and practice. However, the relative impact of core autism traits (e.g. social-communication difficulties), as compared to associated mental health symptoms (e.g. anxiety, depression) on quality of life remains poorly understood. This is despite at least 20%–50% of autistic individuals experiencing associated anxiety and/or depression symptoms. Hence, we measured subjective quality of life in 573 six to thirty-year-olds (autism spectrum disorder N = 344), using two widely validated questionnaires. Adults self-reported on the World Health Organization Quality of Life–Brief instrument. Parents of children/adolescents completed the Child Health and Illness Profile. We assessed individual variability across both measures and modelled associations between quality of life, core autism traits, anxiety, and depression symptoms. Across both age groups and quality of life measures, autistic individuals scored lower than comparison individuals, on average, particularly for physical health in adults (d = −1.24, 95% confidence interval: [−1.56, −0.93]) and school achievement for children/adolescents (d = −1.06, 95% confidence interval: [−1.29, −0.84]). However, a notable proportion of autistic individuals (36%–71% across quality of life domains) did not have reduced quality of life. Across ages and quality of life measures, severity of associated symptoms was significantly related to reduced quality of life on several domains, after accounting for core autism traits. Most notably, depression symptoms were related to reduced physical/psychological well-being in both adults (β ≥ −0.34) and children/adolescents (β = −0.29, 95% confidence interval: [−0.36, −0.14]). For children/adolescents, anxiety symptoms (β ≥ −0.28) and core social-communication difficulties (β ≥ −0.22) were also related to subjective quality of life outcomes. Overall, findings indicate that not all autistic individuals experience reduced subjective quality of life. Variability in quality of life is significantly influenced by associated symptoms, across developmental stage. This may provide a tractable target for mental health services to improve quality of life for autistic individuals over the lifespan.

Lay abstract
Previous studies suggest that some autistic individuals report lower satisfaction, or well-being, with different aspects of everyday life than those without autism. It is unclear whether this might be partly explained by symptoms of anxiety...
and/or depression, which affect at least 20%–50% of autistic people. In this study, we measured individual differences in well-being in 573 six to thirty-year-olds with and without a diagnosis of autism. We investigated whether individual differences in well-being were explained by autism traits (e.g. social-communication difficulties) and/or anxiety and depression symptoms. We showed that, though well-being was lower for some autistic individuals, compared to those without autism, many autistic individuals reported good well-being. Where well-being was reduced, this was particularly explained by depression symptoms, across all ages. For children/adolescents, anxiety and social-communication difficulties were also related to some aspects of well-being. Our study suggests that support and services for improving mental health, especially depression symptoms, may also improve broader outcomes for autistic people.

Keywords
anxiety, autism, depression, quality of life, well-being

Introduction

Defining quality of life

Quality of life (QoL) is a fundamental outcome measure across psychiatry and healthcare, as recognised by the UK National Institute for Health and Care Excellence and World Health Organization (Mukuria et al., 2015; Provenzani et al., 2020; World Health Organization, 1998). Recently, QoL has also been identified as a gold standard for assessing well-being in autism – an outcome measure prioritised by autistic people and their families (McConachie et al., 2015). QoL can be defined as an individual’s satisfaction with their position in life, linked with their context, goals, expectations, standards and concerns (World Health Organization, 1998). Its multifaceted nature means that QoL cannot easily be reduced to a single score and must be considered across several domains, from physical and psychological health to social relationships. Subjective well-being may vary across these domains, each of them influenced by different contributing factors.

QoL in autism

Accumulating evidence suggests that some autistic individuals experience reduced QoL, as compared to neurotypical individuals and those with other neurodevelopmental conditions, including attention deficit/hyperactivity disorder (ADHD; Barneveld et al., 2014; van Heijst & Geurts, 2015). This emphasises that improving QoL outcomes in autism is a key priority for clinical research and practice. Nevertheless, it must be acknowledged that the experiences of autistic people vary substantially (Howlin & Moss, 2012). For example, while many individuals remain highly dependent on their families or support services into adulthood, others live independently – maintaining supportive relationships and regular employment (Howlin et al., 2004). Historically, studies that have highlighted such variability in the outcomes of autistic individuals have largely focused on objective QoL (see Henninger & Taylor, 2012 for a review). This means that they considered quantifiable, ‘normative’ markers of outcome, such as number of friendships, form of employment and contact with services (Billstedt et al., 2011; Bishop-Fitzpatrick et al., 2016; Steinhausen et al., 2016). The focus on objective QoL may be partly explained by the lack of available measurement tools for assessing subjective QoL in autism that are suitable for all ability levels and developmental stages (Ayres et al., 2018). However, the very definition of QoL emphasises its subjective nature, reflecting an individual’s perceptions of their well-being (i.e. how satisfied they are with their friendships, employment etc.; Coghill et al., 2009). Thus, there has been a more recent shift towards establishing individual variability in subjective QoL in autism and identifying the factors that may explain why a proportion of autistic individuals experience QoL reductions.

Existing research regarding subjective QoL outcomes would indicate that, on average, autistic people experience lower subjective well-being than neurotypical individuals, with a large effect size (d = −0.96; van Heijst & Geurts, 2015). This pattern of findings has been particularly reported for QoL domains indexing satisfaction with social relationships (e.g. feeling supported by friends/peers; Graham Holmes et al., 2020; Mason et al., 2018; Moss et al., 2017), psychological health (e.g. positive/negative affect, self-esteem, cognition; Hong et al., 2016) and – for autistic young people – school functioning (Kuhlthau et al., 2013). However, as with objective QoL outcomes, there may be substantial individual variability in the subjective well-being of each autistic person. This variability may also reflect the ‘person-environment fit’, or balance between objective (i.e. societal demands, expectations, accommodations) and subjective (i.e. individuals needs and preferences) outcomes (Billstedt et al., 2011; Henninger & Taylor, 2012).

Factors associated with subjective QoL in autism

Notably, establishing the clinical determinants of subjective QoL reductions is essential for identifying where interventions and support would best be targeted to improve outcomes for some autistic people. Several studies have noted that higher severity of core autism traits, such as social-communication difficulties, are significantly associated with reduced subjective QoL in individuals with and
without autism (Chiang & Wineman, 2014; de Vries & Geurts, 2015; Pisula et al., 2015; van Steensel et al., 2012). In addition, other factors highly implicated in autism, such as differences in executive functioning and sensory processing sensitivities, may also be related to QoL (de Vries & Geurts, 2015; Dijkhuis et al., 2016; Lin & Huang, 2019).

However, far fewer studies have investigated the impact of associated mental health symptoms on QoL in autism. This is despite the fact that ~20%–50% of autistic people experience associated symptoms of anxiety and/or depression (Hollocks et al., 2019; Lai et al., 2019; Simonoff et al., 2008). Furthermore, strong relationships have been identified between mental health symptoms and QoL in the wider population (Rapport et al., 2005). Considering this, there has been a recent call for research based on well-characterised samples of individuals, varying in severity of neurodevelopmental/neuropsychiatric symptoms, to identify how QoL may be attributable to specific symptom dimensions that frequently co-occur (Jonsson et al., 2017).

Some existing research has begun to indicate relationships between associated mental health symptoms and facets of QoL in autism. For instance, elevated anxiety has been found to relate to increased physical health problems, including chronic gastrointestinal symptoms, in young people with autism (Mazurek et al., 2013). In longitudinal models, anxiety and depression symptoms early in development have also been linked to lower life satisfaction, greater social difficulties and reduced adaptive functioning by adulthood (Gotham et al., 2015). Furthermore, current mental health diagnoses are associated with subjective QoL in autistic adults, across domains of physical, psychological, social and environmental well-being, as rated with the World Health Organization Quality of Life–Brief instrument (WHOQoL-BREF; Mason et al., 2018). Generalised internalising problems are also associated with general subjective satisfaction and physical/psychological QoL during childhood, indexed with the Child Health and Illness Profile (Kuhlthau et al., 2013).

Nevertheless, we note some issues that require further investigation. First, previous studies have often utilised clinical or diagnostic cut-points to determine whether associated symptoms are absent or present – an approach which may underestimate the impact of these symptoms on QoL. Indeed, there are several diagnostic challenges to identifying co-occurring mental health/neurodevelopmental symptoms, meaning some individuals never receive a formal diagnosis and therefore remain underrepresented in such research (Hollocks et al., 2019; White et al., 2009). Second, where existing research has taken a dimensional approach to assess the impact of associated symptoms on QoL, across their full range of severity, other factors like core autism traits are not consistently controlled for in analyses (Adams et al., 2019) and/or internalising and emotional problems are considered as a general, unitary construct. This means that it is not possible to estimate the added impact of anxiety and/or depression symptoms in autism, over and above other factors known to influence QoL. Last, almost all existing studies have focused on single age groups, predominantly children (Bishop-Fitzpatrick et al., 2018), even though autism is a lifelong condition for which QoL reductions have been shown to persist into later adulthood (Graham Holmes et al., 2020; Mason et al., 2019; van Heijst & Geurts, 2015).

Hence, in this study, we aimed to investigate (1) individual variability in QoL among children, adolescents and adults on the autism spectrum, across several domains; and (2) their relationship with varying levels of core autism traits and associated symptoms of anxiety and depression. We addressed our aims using data from the European Autism Interventions Multicentre Study for Developing New Medications (EU-AIMS) Longitudinal European Autism Project (LEAP; Charman et al., 2017; Loth et al., 2017) – a well-characterised cohort of autistic males and females, diverse in age (6–30 years) and IQ (50–148). Based on the previous literature reported above, we predicted that autistic individuals would score lower for QoL than comparison individuals, but that we may also detect substantial individual variability in subjective QoL reports. In addition, since associated mental health symptoms have a strong impact on QoL in the wider population, we predicted that anxiety and/or depression symptoms would explain significant variance in QoL, even after accounting for core autism traits.

**Methods**

**Participants**

This study is based on data from the EU-AIMS LEAP cohort (please see Charman et al., 2017; Loth et al., 2017). A total of 573 males and females with and without a diagnosis of autism spectrum disorder (ASD, N = 344), aged 6–30 years and with IQ of 50–148 and available QoL data were included. Participant characteristics and measures included in the current study are shown in Table 1.

ASD and comparison groups did not significantly differ by sex (χ²(1, 573) = 1.80, p = 0.18, φ = 0.06) and differed only nominally on age (Z = 1.95, p = 0.05, d = −0.16, 95% confidence interval (CI): [−0.33, 0.00]). Average IQ was significantly lower in the ASD group than the comparison group (Z = 3.85, p < 0.001, d = −0.32, 95% CI: [−0.49, −0.15]), though both ASD and comparison groups included individuals with mild intellectual disability (IQ ≤ 75) in the child/adolescent (but not adult) age range. This study was approved by ethics committees at each participating site and informed consent/assent was obtained from all participants and their parents, where applicable.

**Materials and procedures**

**QoL measures.** We administered two widely used QoL measures – in adults without intellectual disability, the 26-item self-report WHOQoL-BREF (The WHOQoL Group, 1996) and, for children and adolescents, the
Table 1. Descriptives and group comparisons for participant characteristics.

(a) Adults (18–30 years)

<table>
<thead>
<tr>
<th></th>
<th>ASD</th>
<th>Non-ASD</th>
<th>Group Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>M (SD)</td>
<td>Range</td>
</tr>
<tr>
<td><strong>Sex: Males (Females)</strong></td>
<td>72 (34)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>106</td>
<td>23.08 (3.57)</td>
<td>18–30</td>
</tr>
<tr>
<td><strong>Full-scale IQ</strong></td>
<td>106</td>
<td>105.64 (14.52)</td>
<td>75–148</td>
</tr>
<tr>
<td><strong>SRS-2 (Self)</strong></td>
<td>104</td>
<td>64.58 (10.17)</td>
<td>40–89</td>
</tr>
<tr>
<td><strong>SSP</strong></td>
<td>41</td>
<td>15.07 (26.33)</td>
<td>93–190</td>
</tr>
<tr>
<td><strong>DAWBA Anxiety</strong></td>
<td>95</td>
<td>3</td>
<td>0–4</td>
</tr>
<tr>
<td><strong>DAWBA Depression</strong></td>
<td>84</td>
<td>1</td>
<td>0–5</td>
</tr>
<tr>
<td><strong>DAWBA ADHD</strong></td>
<td>59</td>
<td>0</td>
<td>0–4</td>
</tr>
</tbody>
</table>

ASD: autism spectrum disorder; CI: confidence interval; SRS-2: Social Responsiveness Scale–Second Edition; SSP: Short Sensory Profile; DAWBA: Development and Wellbeing Assessment; ADHD: attention deficit/hyperactivity disorder; $\chi^2$: chi-square statistic (degrees of freedom, sample size); φ: phi effect size for chi-square; Z: statistic for Mann–Whitney comparison; d: Cohen's d effect size [95% confidence intervals].

(b) Children/Adolescents (6–17 years)

<table>
<thead>
<tr>
<th></th>
<th>ASD</th>
<th>Non-ASD</th>
<th>Group Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>M (SD)</td>
<td>Range</td>
</tr>
<tr>
<td><strong>Sex: Males (Females)</strong></td>
<td>173 (65)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>238</td>
<td>12.82 (3.11)</td>
<td>6–17</td>
</tr>
<tr>
<td><strong>Full-scale IQ</strong></td>
<td>230</td>
<td>97.86 (19.55)</td>
<td>53–148</td>
</tr>
<tr>
<td><strong>SRS-2 (Parent)</strong></td>
<td>186</td>
<td>133.62 (25.26)</td>
<td>69–189</td>
</tr>
<tr>
<td><strong>DAWBA Anxiety</strong></td>
<td>193</td>
<td>1</td>
<td>0–5</td>
</tr>
<tr>
<td><strong>DAWBA Depression</strong></td>
<td>184</td>
<td>0</td>
<td>0–4</td>
</tr>
<tr>
<td><strong>DAWBA ADHD</strong></td>
<td>198</td>
<td>3</td>
<td>0–5</td>
</tr>
</tbody>
</table>

(c) Total Sample (6–30 years)

<table>
<thead>
<tr>
<th></th>
<th>ASD</th>
<th>Non-ASD</th>
<th>Group Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>M (SD)</td>
<td>Range</td>
</tr>
<tr>
<td><strong>Sex: Males (Females)</strong></td>
<td>245 (99)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>344</td>
<td>15.98 (5.75)</td>
<td>6–30</td>
</tr>
<tr>
<td><strong>Full-scale IQ</strong></td>
<td>336</td>
<td>100.31 (18.45)</td>
<td>54–148</td>
</tr>
<tr>
<td><strong>SRS-2 (Self)</strong></td>
<td>168</td>
<td>63.11 (10.28)</td>
<td>40–89</td>
</tr>
<tr>
<td><strong>SRS-2 (Parent)</strong></td>
<td>307</td>
<td>72.34 (11.91)</td>
<td>43–90</td>
</tr>
<tr>
<td><strong>SSP</strong></td>
<td>227</td>
<td>137.31 (26.59)</td>
<td>69–190</td>
</tr>
<tr>
<td><strong>DAWBA Anxiety</strong></td>
<td>294</td>
<td>3</td>
<td>0–5</td>
</tr>
<tr>
<td><strong>DAWBA Depression</strong></td>
<td>277</td>
<td>1</td>
<td>0–5</td>
</tr>
<tr>
<td><strong>DAWBA ADHD</strong></td>
<td>243</td>
<td>2</td>
<td>0–5</td>
</tr>
</tbody>
</table>

ASD: autism spectrum disorder; CI: confidence interval; SRS-2: Social Responsiveness Scale–Second Edition; SSP: Short Sensory Profile; DAWBA: Development and Wellbeing Assessment; ADHD: attention deficit/hyperactivity disorder; $\chi^2$: chi-square statistic (degrees of freedom, sample size); φ: phi effect size for chi-square; Z: statistic for Mann–Whitney comparison; d: Cohen’s d effect size [95% confidence intervals].

*Median reported, due to ordinal nature of the scale.

†Effect size for Mann–Whitney U was converted to d using Rosenthal (1994).

‡51 individuals in the child/adolescent age range had IQ < 75 (ASD N=37).

§p < 0.05; ***p < 0.001 (significant after Bonferroni correction; p = 0.05/28).
The WHOQoL-BREF is currently one of the only QoL tools that has been validated for use with autistic adults without intellectual disability (Hong et al., 2016; McConachie et al., 2018). It assesses QoL across four domains: Physical Health (To what extent do you feel that physical pain prevents you from doing what you need to do?); Psychological Health (How much do you enjoy your life?); Social Relationships (How satisfied are you with the support you get from your friends?); and Environment (To what extent do you have the opportunity for leisure activities?). 106 autistic adults and 86 neurotypical adults, aged 18–30 years and with IQ > 75, completed the WHOQoL-BREF. Scores were transformed to a 0–100 scale for comparability with previous reports. Higher scores indicate better QoL. If <20% of values within a domain were missing (Physical Health N = 81, Psychological Health N = 82), we imputed them by taking the mean of non-missing values within that domain, as per the official scoring manual.

The CHIP-CE is a commonly administered parent-report tool that measures QoL across five domains: physical/psychological Comfort (How often did your son/daughter have pain that really bothered him/her?); Satisfaction (How often does your son/daughter feel happy?); Resilience (How often does your son/daughter have an adult he/she can go to for help with a real problem?); Risk Avoidance (How often does your son/daughter do things that are dangerous?); and Achievement (How did he/she do in his/her schoolwork?). We administered the CHIP-CE to parents of 381 children and adolescents – 146 aged 6–11 years (ASD N = 91) and 235 aged 12–17 years (ASD N = 147), including 51 individuals with IQ ≤ 75 (ASD N = 37). We report mean scores, with higher scores reflecting better QoL. Imputation of missing values was not necessary for any domain.

Core autism traits. To measure the impact of current, core autism traits on QoL, we administered the Social Responsiveness Scale–Second Edition (SRS-2; Constantino & Gruber, 2012). We chose this measure because it has been validated for use across a wide age range (e.g. 6–30 years). Higher scores (sex-specific T-norms) indicate more severe difficulties. A self-report version was administered for all adults (i.e. ASD and comparison) aged 18–30 years and a parent-report version for all autistic individuals, as well as comparison individuals aged 6–17 years.

In the child/adolescent group, we also conducted supplementary analyses (Supplementary Table 3), using the Short Sensory Profile (SSP; Tomchek & Dunn, 2007) to index sensory processing differences commonly associated with autism that have been shown to relate to QoL. The SSP was completed by parents across all ages in the ASD group and ages 6–17 years in the comparison group, with lower scores indicating more sensory processing differences.

Statistical analysis

Data were analysed using RStudio®, Version 3.5.1. As the DAWBA is rated on an ordinal scale, we used non-parametric statistics for group comparisons (Mann–Whitney) and correlations (Spearman’s r). Bonferroni correction for multiple comparisons was applied throughout.

First, we assessed mean group differences in QoL scores between ASD and comparison groups, across each domain of the WHOQoL-BREF for adults aged 18–30 years and the CHIP-CE for children/adolescents aged 6–17 years, respectively. We then examined individual variability in QoL within the adult and child/adolescent subsamples from the ASD group, by calculating each individual’s score from the comparison group mean for each QoL domain. We used this criterion to quantify the proportion of autistic individuals scoring within or outside of 1 and 2 standard deviations from the comparison group mean.

Finally, we used linear regression models (‘lm’, function) to establish associations between QoL and core autism traits, anxiety and depression symptoms in the adult and child/adolescent sample, respectively, were entered as dependent variables. Independent variables across all models were age, IQ, sex, core autism traits (SRS-2) and associated symptoms.
Autism 00(0)

To be included in this analysis, individuals had to have available data for all variables in the regression model.

Results

Group comparisons on QoL

First, to establish whether results from the current sample replicated previous studies showing reduced QoL in autism, we compared average QoL scores for the ASD and comparison groups. Across both age groups, on both QoL measures, autistic individuals (as a group) scored significantly lower for QoL than comparison individuals (Table 2; Figure 1). Removing individuals with IQ < 75 (N = 51) from both ASD and comparison groups did not change the pattern of results, nor significance.

The strongest effect size for the difference in QoL between ASD and comparison adults was on the WHOQoL-BREF Physical Health domain (Z = 7.72, p < 0.001, d = −1.24, 95% CI: [−1.56, −0.93]). The strongest effect size for the difference between ASD and comparison children/adolescents was on the CHIP-CE school Achievement domain (Z = 8.92, p < 0.001, d = −1.06, 95% CI: [−1.29, −0.84]).

Individual variability in QoL

Nevertheless, as highlighted by the individual data points presented in Figure 1, there was notable individual variability in QoL scores within both the ASD and comparison groups. Across WHOQoL-BREF domains, between 34.9% (Physical Health) and 54.7% (Environment) of autistic adults scored within 1 standard deviation of the comparison group mean (please see Figure 2). Similarly, across CHIP-CE domains, 43.0% (Achievement) to 66.8% (Resilience) of autistic children/adolescents scored within 1 standard deviation of the comparison group mean.

In contrast, some autistic individuals did have notable QoL reductions, scoring > 2 standard deviations below the comparison group mean. Averaging across WHOQoL-BREF domains, this applied to 22.0% of autistic adults; and averaging across CHIP-CE domains, 18.5% of children/adolescents. Descriptives for the characteristics of individuals from the ASD group who scored within or above 1 standard deviation, as compared to those who scored below 1 standard deviation from the comparison group, are presented in Supplementary Table 2.

Of note, we confirmed that QoL scores in our comparison group corresponded to existing published norms (Hawthorne et al., 2006; Riley et al., 2001), except for CHIP-CE Comfort (comparison group scored higher than norms) and Achievement domains (lower than norms; Supplementary Table 1), indicating that our results were not driven by a particularly low- or high-scoring comparison group.

The influence of core autism traits and associated anxiety/depression symptoms on QoL

Considering the significant individual variability in QoL identified in the previous section, we assessed how this variability may be related to severity of core autism traits and associated anxiety and depression symptoms, within the adult and child/adolescent subsamples from the ASD group. Regression coefficients and model fit statistics are shown in Table 3. Overall, regression models were significant for all WHOQoL-BREF and CHIP-CE domains, except WHOQoL Environment.

Table 2. Descriptives and group comparisons for QoL domains.

(a) WHOQoL-BREF (adults 18–30 years)

<table>
<thead>
<tr>
<th>Domain</th>
<th>ASD</th>
<th>Comparison</th>
<th>Z</th>
<th>p</th>
<th>d [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>M (SD)</td>
<td>Range</td>
<td>N</td>
<td>M (SD)</td>
<td>Range</td>
</tr>
<tr>
<td>Physical Health</td>
<td>106 66.17 (16.00)</td>
<td>14–96</td>
<td>86</td>
<td>83.13 (9.96)</td>
<td>54–100</td>
</tr>
<tr>
<td>Psychological Health</td>
<td>106 55.09 (18.06)</td>
<td>4–100</td>
<td>86</td>
<td>71.38 (14.14)</td>
<td>25–100</td>
</tr>
<tr>
<td>Social Relationships</td>
<td>105 50.61 (21.34)</td>
<td>0–92</td>
<td>86</td>
<td>73.35 (17.43)</td>
<td>17–100</td>
</tr>
<tr>
<td>Environment</td>
<td>64 63.64 (15.92)</td>
<td>31–97</td>
<td>47</td>
<td>71.81 (15.59)</td>
<td>28–100</td>
</tr>
</tbody>
</table>

(b) CHIP-CE (Children/Adolescents 6–17 years)

<table>
<thead>
<tr>
<th>Domain</th>
<th>ASD</th>
<th>Comparison</th>
<th>Z</th>
<th>p</th>
<th>d [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>M (SD)</td>
<td>Range</td>
<td>N</td>
<td>M (SD)</td>
<td>Range</td>
</tr>
<tr>
<td>Satisfaction</td>
<td>238 3.50 (0.64)</td>
<td>1.67–5.00</td>
<td>143</td>
<td>4.04 (0.47)</td>
<td>2.33–5.00</td>
</tr>
<tr>
<td>Comfort</td>
<td>238 4.18 (0.50)</td>
<td>2.83–5.00</td>
<td>143</td>
<td>4.53 (0.43)</td>
<td>3.00–5.00</td>
</tr>
<tr>
<td>Resilience</td>
<td>238 3.82 (0.48)</td>
<td>2.50–5.00</td>
<td>143</td>
<td>4.05 (0.45)</td>
<td>2.50–4.88</td>
</tr>
<tr>
<td>Risk Avoidance</td>
<td>236 4.08 (0.52)</td>
<td>2.62–5.00</td>
<td>142</td>
<td>4.38 (0.42)</td>
<td>2.12–5.00</td>
</tr>
<tr>
<td>Achievement</td>
<td>223 3.06 (0.65)</td>
<td>1.12–4.62</td>
<td>140</td>
<td>3.72 (0.57)</td>
<td>1.62–5.00</td>
</tr>
</tbody>
</table>

ASD: autism spectrum disorder; CI: confidence interval; WHOQoL-BREF: World Health Organization Quality of Life–Brief instrument; CHIP-CE: Child Health and Illness Profile.

*p < 0.01, ***p < 0.006 (significant after Bonferroni correction; p = 0.05/9).
For autistic adults, associated depression symptom severity was the only significant predictor of reduced QoL, after holding age, IQ, sex, core autism traits and anxiety symptoms constant. Significant associations between increasing depression symptoms and reduced QoL were apparent across WHOQoL-BREF domains of Physical Health ($\beta = -0.38$, $p = 0.001$, 95% CI for $\beta$: $[-0.40, -0.10]$), Psychological Health ($\beta = -0.34$, $p = 0.002$, 95% CI for $\beta$: $[-0.37, -0.08]$), and Social Relationships ($\beta = -0.40$, $p < 0.001$, 95% CI for $\beta$: $[-0.44, -0.12]$).

CHIP-CE: children/adolescents 6–17 years. Similar to findings from the adult group, in the child/adolescent sample, associated depression symptom severity was a significant predictor of reduced physical/psychological Comfort ($\beta = -0.29$, $p < 0.001$, 95% CI for $\beta$: $[-0.36, -0.14]$), after holding age, IQ, sex, core autism traits and anxiety symptoms constant.

**Figure 1.** Boxplots showing group differences on QoL domains: (a) WHOQoL-BREF (adults 18–30 years); (b) CHIP-CE (children/adolescents 6–17 years). Individual data points are overlaid. The black diamond represents the mean. **p < 0.01; ***p < 0.006 (significant after Bonferroni correction; $p = 0.05/9$).

**Figure 2.** Stacked bar graph showing percentage of autistic individuals with QoL scores $\pm 1$ or 2 standard deviations from the comparison mean on each QoL domain of the WHOQoL-BREF and CHIP-CE, respectively.
Table 3. Regression model fit and coefficients showing relationships within the autism group between WHOQoL-BREF domains for adults aged 18–30 years (N=75) and CHIP-CE domains for children/adolescents aged 6–17 years (N=180), with demographic factors, core autism traits and anxiety/depression symptoms.

### WHOQoL-BREF (adults 18–30 years)

<table>
<thead>
<tr>
<th>WHOQoL-BREF (adults 18–30 years)</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical Health</td>
<td>Psychological Health</td>
<td>Social Relationships</td>
<td>Environment</td>
<td></td>
</tr>
<tr>
<td>β [95% CI]</td>
<td>β [95% CI]</td>
<td>β [95% CI]</td>
<td>β [95% CI]</td>
<td></td>
</tr>
<tr>
<td>Demographic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.01 [−0.18, 0.21]</td>
<td>−0.04 [−0.23, 0.14]</td>
<td>−0.03 [−0.23, 0.18]</td>
<td>−0.02 [−0.23, 0.22]</td>
</tr>
<tr>
<td>IQ</td>
<td>−0.05 [−0.27, 0.15]</td>
<td>−0.17 [−0.37, 0.03]</td>
<td>0.002 [−0.22, 0.22]</td>
<td>−0.15 [−0.39, 0.07]</td>
</tr>
<tr>
<td>Sex</td>
<td>0.14 [−0.07, 0.36]</td>
<td>0.08 [−0.12, 0.29]</td>
<td>−0.15 [−0.39, 0.07]</td>
<td>−0.15 [−0.39, 0.07]</td>
</tr>
<tr>
<td>Core traits</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRS-2 (Self)</td>
<td>−0.05 [−0.29, 0.19]</td>
<td>−0.26 [−0.49, −0.03]</td>
<td>−0.23 [−0.50, 0.02]</td>
<td>−0.23 [−0.50, 0.02]</td>
</tr>
<tr>
<td>Associated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAWBA Anxietya</td>
<td>−0.12 [−0.30, 0.10]</td>
<td>−0.07 [−0.25, 0.13]</td>
<td>0.04 [−0.18, 0.24]</td>
<td>0.04 [−0.18, 0.24]</td>
</tr>
<tr>
<td>DAWBA Depressiona</td>
<td>−0.38 [−0.40, −0.10]***</td>
<td>−0.34 [−0.37, −0.08]***</td>
<td>−0.40 [−0.44, −0.12]***</td>
<td>−0.40 [−0.44, −0.12]***</td>
</tr>
<tr>
<td>Model fit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F(6, 75) = 4.39, p &lt; 0.001***, ηp² = 0.16 (20.1%)</td>
<td>F(6, 75) = 6.24, p &lt; 0.001***, ηp² = 0.28 (28.0%)</td>
<td>F(6, 74) = 3.62, p &lt; 0.001***, ηp² = 0.16 (16.4%)</td>
<td>F(6, 41) = 2.49, p = 0.04*, ηp² = 0.15 (15.9%)</td>
<td></td>
</tr>
</tbody>
</table>

### CHIP-CE (Children/Adolescents 6–17 years)

<table>
<thead>
<tr>
<th>CHIP-CE (Children/Adolescents 6–17 years)</th>
<th>Satisfaction</th>
<th>Comfort</th>
<th>Resilience</th>
<th>Risk Avoidance</th>
<th>Achievement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β [95% CI]</td>
<td>β [95% CI]</td>
<td>β [95% CI]</td>
<td>β [95% CI]</td>
<td>β [95% CI]</td>
</tr>
<tr>
<td>Demographic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>−0.13 [−0.29, −0.01]*</td>
<td>0.07 [−0.06, 0.20]</td>
<td>−0.23 [−0.39, −0.09]***</td>
<td>0.24 [0.11, 0.40]***</td>
<td>−0.02 [−0.14, 0.13]</td>
</tr>
<tr>
<td>IQ</td>
<td>−0.06 [−0.20, 0.07]</td>
<td>0.05 [−0.07, 0.18]</td>
<td>0.07 [−0.07, 0.22]</td>
<td>0.06 [−0.09, 0.20]</td>
<td>0.34 [0.22, 0.50]***</td>
</tr>
<tr>
<td>Sex</td>
<td>−0.005 [−0.15, 0.14]</td>
<td>0.07 [−0.06, 0.20]</td>
<td>−0.06 [−0.22, 0.09]</td>
<td>−0.18 [−0.36, −0.05]***</td>
<td>−0.16 [−0.32, −0.03]***</td>
</tr>
<tr>
<td>Core traits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRS-2 (Parent)</td>
<td>−0.22 [−0.37, −0.08]***</td>
<td>−0.14 [−0.27, −0.01]***</td>
<td>−0.07 [−0.22, 0.08]</td>
<td>−0.19 [−0.34, −0.04]***</td>
<td>−0.34 [−0.48, −0.20]***</td>
</tr>
<tr>
<td>Associated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAWBA Anxietya</td>
<td>−0.28 [−0.34, −0.12]***</td>
<td>−0.33 [−0.35, −0.15]***</td>
<td>−0.01 [−0.12, 0.11]</td>
<td>0.03 [−0.09, 0.15]</td>
<td>0.003 [−0.11, 0.11]</td>
</tr>
<tr>
<td>DAWBA Depressiona</td>
<td>−0.28 [−0.38, −0.14]***</td>
<td>−0.39 [−0.36, −0.14]***</td>
<td>−0.22 [−0.32, −0.07]***</td>
<td>−0.18 [−0.29, −0.04]***</td>
<td>−0.15 [−0.24, −0.01]***</td>
</tr>
<tr>
<td>Model fit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F(6, 180) = 13.69, p &lt; 0.001***, ηp² = 0.29 (29.0%)</td>
<td>F(6, 180) = 6.24, p &lt; 0.001***, ηp² = 0.16 (16.4%)</td>
<td>F(6, 180) = 3.62, p = 0.003***, ηp² = 0.15 (15.9%)</td>
<td>F(6, 180) = 4.45, p &lt; 0.001***, ηp² = 0.15 (15.9%)</td>
<td>F(6, 180) = 4.96, p &lt; 0.001***, ηp² = 0.15 (15.9%)</td>
<td></td>
</tr>
</tbody>
</table>

CI: confidence interval; SRS-2: Social Responsiveness Scale–Second Edition; β: standardised regression coefficient [95% confidence intervals]; F: F test for model significance (degrees of freedom, sample size); ηp²: partial eta-squared effect size. Residuals from regression models were approximately normally distributed and collinearity diagnostics suggested no multicollinearity between variables.

aDAWBA scores were based on: Model a) multi-informant N = 58; self N = 107; parent N = 8; Model b) multi-informant N = 94; self N = 6; parent N = 207.

*p < 0.05, **p < 0.01, ***p < 0.008 (significant after Bonferroni correction; p = 0.05/6). The significance of bold values is ***p < 0.008.
Anxiety symptoms were also significantly associated with reduced physical/psychological Comfort in this age group ($\beta = -0.33$, $p < 0.001$, 95% CI for $\beta$: $[-0.35, -0.15]$), holding other factors constant.

Furthermore, both anxiety ($\beta = -0.28$, $p < 0.001$, 95% CI for $\beta$: $[-0.34, -0.12]$) and depression symptoms ($\beta = -0.28$, $p < 0.001$, 95% CI for $\beta$: $[-0.38, -0.14]$) significantly contributed to decreased overall Satisfaction and depression symptoms to reduced Resilience ($\beta = -0.22$, $p = 0.003$, 95% CI for $\beta$: $[-0.32, -0.07]$).

In terms of core autism traits, higher SRS-2-rated difficulties were significantly related to decreased QoL on the CHIP-CE Satisfaction ($\beta = -0.22$, $p < 0.001$, 95% CI for $\beta$: $[-0.37, -0.08]$) and Achievement domains ($\beta = -0.34$, $p < 0.001$, 95% CI for $\beta$: $[-0.48, -0.20]$).

Finally, considering demographic factors, higher IQ was significantly related to higher scores on the Achievement domain ($\beta = 0.34$, $p < 0.001$, 95% CI for $\beta$: $[0.22, 0.50]$) and older age with decreased Resilience ($\beta = -0.23$, $p = 0.002$, 95% CI for $\beta$: $[-0.39, -0.09]$) but increased Risk Avoidance ($\beta = 0.24$, $p < 0.001$, 95% CI for $\beta$: $[0.11, 0.40]$). All these effects survived Bonferroni correction – additional, nominally significant results ($p < 0.05$ threshold) are flagged in Table 3. Supplementary analyses including SSP-rated sensory processing and DAWBA-rated ADHD symptoms for the child/adolescent group are presented in Supplementary Table 3.

**Discussion**

*Individual variability in QoL in autism*

This study is one of the first to demonstrate individual variability in QoL in autism, alongside group-level comparisons, across children, adolescents and adults, including those with mild intellectual disability. At the group level, QoL was significantly lower for autistic individuals, across all age groups, than comparison individuals. The area of QoL most reduced for autistic adults was physical health and, for children and adolescents, school achievement. Yet, analyses also revealed that, at the individual level, a notable proportion of autistic individuals in this study did not experience reduced QoL. In other words, many autistic individuals (36%–71% across QoL domains) reported, or were reported to have, a good QoL (according to thresholds on the subjective QoL measures utilised here) – emphasising the importance of accounting for subjective satisfaction when assessing outcomes in autism (Henninger & Taylor, 2012).

Our findings extend reports of individual variability in objective QoL in autism (Billstedt et al., 2011; Bishop-Fitzpatrick et al., 2016; Howlin et al., 2004), highlighting that variability is also prominent for subjective QoL. Therefore, group-level findings reported in QoL studies cannot be generalised to all autistic individuals. Moreover, understanding the strengths and protective factors that promote good QoL for some autistic individuals could inform best practice for improving QoL in those for whom it is reduced. For instance, access to social support and engaging in leisure activities and physical exercise have been shown to promote good QoL for some autistic people (Bishop-Fitzpatrick et al., 2017; Hamm & Yun, 2019; Mason et al., 2018; Renty & Roeyers, 2006). Overall, the investigation of individual differences in this study was aided by the multi-domain structure of the QoL instruments administered, which are invaluable for informing individualised intervention and support, since they identify what a good outcome means for each individual and the specific areas they may be struggling most (Coghill et al., 2009).

**Associated symptoms negatively impact QoL in autism, across development**

Accordingly, though some autistic individuals report a QoL comparable to the majority of neurotypical individuals, it is important to understand the clinical determinants driving reduced QoL for those who do not. Results of this study showed that, across ages and different QoL measures (i.e. adults and children/adolescents; WHOQoL-BREF and CHIP-CE), higher severity of depression symptoms was significantly related to reduced QoL in individuals with ASD. Most notably, depression symptoms were strongly related to both physical and psychological well-being in adults (WHOQoL-BREF Physical/Psychological Health domains) and children/adolescents (CHIP-CE Comfort domain).

These findings are consistent with previous reports from general population samples, showing that depression symptoms are a key driver of QoL reductions (Rapaport et al., 2005; Roberts et al., 2014). In addition, it is noteworthy that depression symptoms were associated with physical, as well as psychological, well-being across age groups. Higher rates of physical health problems, such as epilepsy, gastrointestinal issues and inflammatory conditions, have been reported in ASD, as compared to the general population – likely underpinned by genetic and other biological factors (Bauman, 2010; Croen et al., 2015). Some physical health concerns commonly associated with autism, such as weight gain and sleep disturbance, may also be elevated as a side effect of medication use (Howes et al., 2018). Nonetheless, the increasingly acknowledged interconnection between mental and physical health indicates that mental health symptoms, like depression, may exacerbate physical health concerns and vice versa (Firth et al., 2019). Furthermore, mental health problems may present a barrier to accessing services (e.g. anxieties around healthcare settings, mental health perceived as ‘challenging behaviour’), increasing unmet healthcare needs (Doherty et al., 2020; Mason et al., 2018; Nicolaidis et al., 2013). Therefore, a targeted focus on improving mental health for autistic individuals may also
aid in the wider management of physical health concerns commonly experienced in autism and individuals’ subjective satisfaction with their physical well-being.

Further to depression symptoms, in the child/adolescent group, we also identified relationships between anxiety and ADHD symptoms with QoL. First, increasing anxiety symptoms were significantly related to lower physical/psychological well-being and poorer overall satisfaction in this age group. Second, higher ADHD symptom severity was related to significantly reduced risk avoidance (Supplementary Table 3). It is possible that the relationships between associated symptoms and QoL reported here may be equally applicable to other neurodevelopmental conditions. For example, in accordance with the current report, a previous study of children with a primary diagnosis of ADHD showed that ADHD symptom severity was strongly, negatively related to risk avoidance and school achievement, also rated by the CHIP-CE (Coghill & Hodgkins, 2016). Thus, relationships between specific symptom dimensions and QoL outcomes may cross diagnostic boundaries – a hypothesis that requires future research including multiple diagnostic groups (e.g. ASD, anxiety/depressive disorders and ADHD) to be assessed in full. In addition, the fact that we did not identify associations between anxiety and QoL in the adult group in regression models, after holding other factors constant (in contrast to some previous reports; Lin & Huang, 2019; Smith et al., 2019), may further highlight the importance of considering the role and impact of depression symptoms for autistic adults. For instance, associations between anxiety and QoL could be partly mediated by co-occurring depression in some autistic adults, yet depression symptoms have rarely been assessed in previous reports.

As noted in the introductory section, previous studies that have also demonstrated significant associations between depression and QoL in autism have focused on individuals who meet diagnostic threshold for mental health symptom severity and/or are recruited from clinical settings (Mason et al., 2018, 2019; Park et al., 2019). The current findings demonstrate that symptoms which do not meet threshold for a clinical diagnosis can still have a notable impact on QoL, and therefore subtle/subthreshold indications for mental health in autistic individuals need to be routinely screened for and evaluated carefully.

**Core autism traits are associated with aspects of QoL in children/adolescents with autism**

Aside from associated symptoms, there was some evidence for a relationship between core autism traits and QoL in this study, most prominently in children and adolescents. For instance, higher social-communication difficulties were associated with decreased overall satisfaction and school achievement – the QoL domain within which children/adolescents were also reported to experience the lowest well-being. This pattern of results was true after holding co-occurring anxiety and depression symptoms constant, which is important to note since social functioning can be impacted by mental health (e.g. anxiety/low mood leading to social difficulties; Cuve et al., 2018) and vice versa (e.g. social withdrawal leading to anticipatory anxiety/loneliness; Bellini, 2006; Hedley et al., 2018).

School settings are often large, complex social and sensory environments, which can be challenging for some young people on the autism spectrum. Many autistic young people face peer victimisation and bullying and report difficulties managing the pressures of the classroom environment (e.g. too fast-paced) and barriers for good communication with teachers (Sproston et al., 2017; van Roekel et al., 2010). Although around 71% of British children diagnosed with ASD attend mainstream school and spend most of their time in educational settings, there are currently few consistent, formal regulations in place to support them (Mandy et al., 2016; National Autistic Society, 2019). Furthermore, though there is increasing evidence for the potential effectiveness of school-based interventions to support autistic young people, many of these are yet to be translated to real-world practice (Anderson et al., 2017; Sutton et al., 2018). Hence, it is imperative to continue to develop strong research partnerships with schools to robustly evaluate the feasibility and effectiveness of diverse educational strategies for improving the QoL outcomes of young people on the autism spectrum.

For the adult group, we found less convincing evidence for relationships between core autism traits and QoL than in children/adolescents, overall. A simple explanation for this could be that the areas of QoL most affected by autism traits in our children/adolescent group (e.g. school achievement) are not reflected in the WHOQoL-BREF, or that the adult group did not include individuals with IQ < 75 (who may also present with more prominent autistic traits). However, it is also possible that some autistic individuals develop coping strategies for their difficulties associated with autism, but become more vulnerable to mental health problems across development. For instance, core autism traits generally become apparent within the first 2–5 years after birth. In contrast, associated symptoms, particularly depression, seem to emerge most commonly from late childhood and early adolescence (Ghaziuddin et al., 2002; Mayes et al., 2011; van Steensel et al., 2011). Indeed, clinical observations indicate that a proportion of autistic adults develop strategies to manage or ‘camouflage’ (i.e. mask) their difficulties associated with autism. In the long term, camouflaging requires high emotional and physical exertion – a previously reported risk factor for depression severity in autistic adults (Hull et al., 2017; Lai et al., 2017).

If valid, this interpretation implies that a decrease in severity of difficulties associated with autism should not be equated with QoL improvement, in the absence of direct QoL measurement. Indeed, intervention success is often
assessed according to proximal outcomes (e.g. symptom reduction). However, more distal outcomes (e.g. QoL) tend to suggest fewer treatment gains in the areas of everyday functioning that may be particularly important to many autistic people and their families (Fletcher-Watson & McConachie, 2015; McConachie et al., 2015). For example, though cognitive behavioural therapy (CBT) is the most widely supported intervention approach for managing anxiety symptoms in autism (Kreslins et al., 2015; Sukhodolsky et al., 2013; White et al., 2018), improvements in QoL following CBT are not consistently identified (Flygare et al., 2020; van Steensel & Bogels, 2015).

Nevertheless, given that mental health symptoms in ASD can be modified by interventions, including CBT and mindfulness-based therapies (Gaigg et al., 2020), targeting these symptoms may hold potential for improving broader QoL outcomes. As research efforts to modify and develop novel interventions for improving mental health for autistic people evolve (see Cooper et al., 2018; Russell et al., 2019), our findings suggest that QoL is an informative outcome measure, beyond symptom severity. In further support of this, there is existing evidence that diverse outcomes measures in autism may have different contributing factors. For instance, previous data from the LEAP cohort have shown that parent-rated adaptive functioning (i.e. the ability to respond to ‘normative’ societal demands, such as socialisation with peers and everyday skills like washing/dressing) was predicted by core social-communication difficulties but not co-occurring mental health symptoms (Tillmann et al., 2019), whereas here we demonstrate that subjective QoL is strongly associated with mental health. These contrasting findings highlight the need for multiple measures of outcome in autism. Within such a framework, QoL tools have the potential to inform individualised approaches by indicating which outcomes are most meaningful for each person and the areas in which they may be experiencing most difficulties, thereby indicating primary intervention targets – for example, managing physical health problems or prioritising school-based support.

**Strengths and limitations**

This study has a major strength in its heterogeneous sample of well over 500 males and females with and without autism, across developmental stage (6–30 years) and of a wide IQ range (50–148). These sample characteristics made it possible to establish that associated symptoms, particularly depression, are related to specific QoL outcomes in autism, across all developmental stages and levels of functioning. Nevertheless, we also note some limitations.

First, some authors have suggested that there may be overlap between measures of mental health symptoms and QoL measures (Coghill et al., 2009). In other words, it is possible that associations between anxiety and/or depression symptoms with psychological well-being were present because different questionnaire measures were indexing the same, or similar, experiences. However, from a theoretical perspective, the wide-ranging areas of everyday life and well-being that constitute QoL go beyond core psychiatric diagnostic criteria. In support of this, it should be noted that associations were apparent between depression symptoms and three out of four QoL domains of the WHOQoL-BREF in autistic adults, not just the psychological health domain. Similarly, depression symptoms were related to overall satisfaction in children/adolescents, in addition to physical/psychological health. This would suggest that the impact of depression symptoms on QoL in autism is more generalised, rather than specific to issues directly reflecting mental health.

A second limitation is that a self-report QoL measure was administered for adults without intellectual disability and a different parent-report measure for children and adolescents (including those with intellectual disability), meaning results from the adult and child/adolescent samples were not directly comparable. Previous research suggests that parents tend to rate the QoL of their son or daughter lower than their son or daughter would rate themselves (Hong et al., 2016; Jonsson et al., 2017) and different QoL measures use different item wordings for QoL domains. The lack of direct comparability of QoL measures across age groups in currently available QoL tools may reflect that priorities and concerns naturally evolve across development and particular outcomes (e.g. ability to complete schoolwork) are age-specific (Jonsson et al., 2017). Partly as a result of methodological challenges pertaining to age and development, there are currently few widely validated QoL measures for autistic individuals, particularly for those with mild intellectual disability and where novel measures are being developed, they are currently designed for specific age groups (e.g. adults only). The development of validated and robust QoL tools, accessible for individuals with difficulties in reading comprehension and/or speech and language, is thus an important area for future research (Ayres et al., 2018; McConachie et al., 2018). Despite this limitation, we identified a similar effect of depression symptom severity on physical and psychological well-being, across ages and different QoL measures. In addition, it was possible to collect self-report data from autistic adults with IQ > 75 in this study, further supporting that self-report tools are a valid method for assessing subjective QoL in ASD (Shipman et al., 2011).

**Conclusion**

At the group level, average QoL ratings were significantly lower for autistic than comparison individuals, particularly for physical health in adults and school achievement in children and adolescents. This indicates that physical well-being and school support are key priorities for clinical research and practice, in the context of autism. Nevertheless,
at the individual level, a notable proportion of autistic individuals reported a good QoL. Where QoL was reduced, this was most consistently accounted for by the severity of associated mental health symptoms, across age groups and QoL measures. In particular, associated depression symptoms impacted both physical and psychological well-being in children, adolescents and adults on the autism spectrum. In children and adolescents, anxiety, ADHD and core social-communication difficulties were also related to specific QoL outcomes. Taken together, these findings show that associated symptoms, particularly depression, must be specifically evaluated and targeted in order to improve the QoL outcomes of autistic people across development, using individualised approaches.

Acknowledgements

We thank all participants and their families for their time and effort in participating in the study. We also acknowledge the contributions of the EU-AIMS Consortium: Jumana Ahmad, Sara Ambrosino, Bonnie Auyeung, Simon Baron-Cohen, Sarah Baumeister, Christian Beckmann, Sven Bölte, Thomas Bourgeron, Carsten Bours, Michael Brammer, Daniel Brandeis, Claudia Brogna, Yvette de Bruijn, Bhismadev Chakrabarti, Ineke Cornelissen, Flavio Dell’ Acqua, Guillaume Dumas, Christine Ecker, Claire Ellis, Jessica Faulkner, Vincent Frouin, Pilar Garcés, David Goyard, Hannah Hayward, Joerg Hipp, Mark H. Johnson, Prantik Kundu, Meng-Chuan Lai, Xavier Liogier D’ardhuy, Michael Lombardo, David J. Lythgoe, René Mandl, Luke Mason, Andreas Meyer-Lindenberg, Carolin Moessnang, Nico Mueller, Laurence O’Dwyer, Michael Oldenhinkel, Bob Oranje, Gahan Pandina, Antonio M. Persico, Barbara Ruggeri, Amber Ruigrok, Jessica Sabet, Roberto Sacco, Roberto Toro, Heike Tost, Jack Waldman, Steve C.R. Williams, Caroline Wooldridge and Marcel P. Zwiers.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: B.F.M.O. was supported by a studentship award from the Sackler Institute for Translational Neurodevelopment during this project. A.S.J.C. is a consultant for Servier Laboratories and is involved in clinical trials conducted by Servier. The present work is not associated with this relationship. T.C. reports grants from Innovative Medicines Initiative, during the conduct of the study; grants from Medical Research Council; grants from National Institute of Health Research; grants from MQ; grants from Autistica; grants from Charles Hawkins Fund; grants from The Waterloo Foundation, grants from H2020 (EU); personal fees from Guilford; personal fees from Sage; personal fees from F. Hoffmann-La Roche, outside the submitted work. T.B. reports grants from European Union, during the conduct of the study; personal fees from Actelion, personal fees from Hexal Pharma, personal fees from Lilly, personal fees from Lundbeck, personal fees from Medice, personal fees from Neurim Pharmaceuticals, personal fees from Novartis, personal fees from Shire, grants from Vivopharma, personal fees from Hogrefe, personal fees from Kohlhammer, personal fees from CIP Medien, personal fees from Oxford University Press, outside the submitted work. J.B. has been in the past 3 years a consultant to/member of advisory board of/ and/or speaker for Janssen Cilag BV, Eli Lily, Lundbeck, Shire, Roche, Novartis, Medice and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents and royalties. E.S. receives support from the National Institute of Health Research (NIHR) Programme Grant for Applied Research, a Senior Investigator Award and through the NIHR South London and Maudsley NIHR Biomedical Research Centre. She also receives funding from the European Medicine Innovative Medicines Initiative (EU-AIMS), the Medical Research Council, the Economic and Social Research Council, Autistica and the Maudsley Charity. D.M. receives consultancy fees from F. Hoffmann-La Roche and is also supported by the NIHR Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. There are no other declarations.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study received support from two EU IMI initiatives (EU AIMS and AIMS-2-TRIALS). EU-AIMS received support from the IMI Joint Undertaking (JU) under grant agreement no. 115300, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013), from the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contribution, and from Autism Speaks. AIMS-2-TRIALS receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 777394. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Autism Speaks, Autistica, SFARI.

ORCID iDs

Bethany FM Oakley https://orcid.org/0000-0002-1968-134X
Tony Charman https://orcid.org/0000-0003-1993-6549
Tobias Banaschewski https://orcid.org/0000-0003-4595-1144
Emily Simonoff https://orcid.org/0000-0002-5450-0823

Supplemental material

Supplemental material for this article is available online.

References


